Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future Outlook

Abstract

AbstractBackgroundParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non‐motor symptoms, primarily because of the impairment of dopaminergic neurons. Long‐term use of levodopa, the standard PD treatment, often results in fluctuating therapeutic effects and dyskinesia, necessitating alternative therapies.ObjectivesThis review aims to synthesize current insights and clinical experiences with foslevodopa‐foscarbidopa, focusing on its pharmacokinetics, efficacy, and safety profile, to evaluate its potential in transforming PD therapy.MethodsA systematic literature search was conducted up to November 2023 using databases PubMed, Web of Science, and Cochrane Library. The search yielded eight eligible articles, including pharmacological studies, case reports, observational studies, and controlled trials. No language restrictions were applied.ResultsFoslevodopa and foscarbidopa, as prodrugs of levodopa and carbidopa, exhibited excellent chemical stability and solubility, facilitating continuous subcutaneous infusion. Clinical trials demonstrated that these prodrugs maintain stable levodopa levels, thereby addressing the limitations of oral levodopa therapy. Phase 1 and 3 studies indicated significant improvements in motor function and quality of life in advanced PD patients. However, a higher incidence of treatment‐emergent adverse events, mainly infusion site reactions, was observed compared to oral therapies.ConclusionsFoslevodopa‐foscarbidopa emerges as a promising alternative for advanced PD treatment, offering sustained symptom control. Its efficacy in managing motor fluctuations and dyskinesia makes it a viable option in the PD therapeutic spectrum. Future research should focus on long‐term safety, economic impact, and broader accessibility. Foslevodopa‐foscarbidopa is now commercially distributed in many countries in Europe and in Japan.